478 reports of this reaction
2.4% of all ALPELISIB reports
#11 most reported adverse reaction
VOMITING is the #11 most commonly reported adverse reaction for ALPELISIB, manufactured by Novartis Pharmaceuticals Corporation. There are 478 FDA adverse event reports linking ALPELISIB to VOMITING. This represents approximately 2.4% of all 20,016 adverse event reports for this drug.
Patients taking ALPELISIB who experience vomiting should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VOMITING is a less commonly reported adverse event for ALPELISIB, but still significant enough to appear in the safety profile.
In addition to vomiting, the following adverse reactions have been reported for ALPELISIB:
The following drugs have also been linked to vomiting in FDA adverse event reports:
VOMITING has been reported as an adverse event in 478 FDA reports for ALPELISIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
VOMITING accounts for approximately 2.4% of all adverse event reports for ALPELISIB, making it a notable side effect.
If you experience vomiting while taking ALPELISIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.